Anti-EGFR Recombinant Antibody (Nimotuzumab) (CAT#: TAB-710)

Figure 1 EGFR signal transduction and effects of EGFR inhibition on downstream targets.

Scheme of EGFR signal transduction. Nimotuzumab and PD153035 are inhibitors of EGFR: Activation of EGFR results in activation of Akt signaling which relieves a TSC1/TSC2 as well as PRAS40 (via phosphorylation of Thr246)-mediated inhibition of mTORC1. RPS6 phosphorylation at Ser235/236 and Ser 240/244 is regulated by mTORC1.

Ronellenfitsch, M. W., Zeiner, P. S., Mittelbronn, M., Urban, H., Pietsch, T., Reuter, D., ... & Harter, P. N. (2018). Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. Acta neuropathologica communications, 6(1), 81.

Figure 2 EGFR signal transduction and effects of EGFR inhibition on downstream targets.

LNT-229 cells were incubated in serum-free DMEM for 90 min with vehicle (DMSO control), PD153035 (dissolved in DMSO), control solution for nimotuzumab (placebo solution of the trial) or 1 ?M nimotuzumab as indicated. Cellular lysates were analyzed by immunoblot with antibodies as indicated.

Ronellenfitsch, M. W., Zeiner, P. S., Mittelbronn, M., Urban, H., Pietsch, T., Reuter, D., ... & Harter, P. N. (2018). Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. Acta neuropathologica communications, 6(1), 81.

Figure 1 Anti-EGFR Recombinant Antibody (TAB-710) in WB

Western blot analysis of TAB-710 was performed with human EGFR protein (His Tag).

TAB-710 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-anti-human IgG
Lane 1: Reducing Antigen (0.1 μg)
Lane 2: Reducing Antigen (0.3 μg)
Lane 3: Reducing Antigen (0.6 μg)

Figure 2 Anti-EGFR Recombinant Antibody (TAB-710) in ELISA

ELISA analysis of TAB-710 was performed by coating with human EGFR protein (His Tag).

The secondary antibody: HRP-anti-human IgG